Shire submits application for FDA approval of Gaucher drug

09/1/2009 | American City Business Journals

Shire filed a new-drug application with the FDA for velaglucerase alfa, a treatment for patients with Type 1 Gaucher disease, ahead of schedule. The company expedited development of the drug amid a shortage of rival drug Cerezyme, caused by a viral contamination at Genzyme's manufacturing facility in Boston.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA